Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QTRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsQuanterix shareholders reject equity compensation plan extension at 2026 annual meeting
Filed June 10, 2026 · Period ending June 9, 2026 · ~1 min read
Key Changes
-
medium
Stockholders voted down proposal to extend the 2017 equity incentive plan through 2031, with 24 million votes against versus 9.7 million for. This limits management's ability to grant stock-based compensation and may require alternative compensation arrangements.
Item 5.07 verify on EDGAR → -
low
Shareholders approved executive compensation in advisory vote with 27.7 million for versus 3.9 million against, indicating general support for current pay practices despite rejecting the equity plan extension.
Item 5.07 verify on EDGAR → -
low
William P. Donnelly and Ivana Magovčević-Liebisch elected as independent directors for one-year terms expiring in 2027, receiving approximately 30.9 million and 30.3 million votes respectively.
Item 5.07 verify on EDGAR → -
low
KPMG LLP ratified as independent auditor for fiscal 2026 with overwhelming support of 38.7 million votes, a routine annual approval.
Item 5.07 verify on EDGAR →
Summary
Quanterix held its 2026 annual meeting on June 9, where shareholders delivered a mixed message on compensation. While they approved executive pay in an advisory vote and ratified routine matters like director elections and the auditor appointment, they rejected management's proposal to extend the company's equity incentive plan through 2031 by a significant margin.
The rejection suggests shareholder concerns about dilution or equity compensation practices. For retail investors, the failed equity plan proposal is the key takeaway. Without an extended equity plan, Quanterix may face challenges recruiting and retaining talent through stock-based compensation, a common practice in the biotech sector.
Management will likely need to return with a revised proposal or explore alternative compensation structures. Watch for announcements about how the company plans to address equity compensation going forward, particularly in upcoming quarterly filings or proxy materials.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify